An AllTrials project

NCT04377659: An ongoing trial by Memorial Sloan Kettering Cancer Center

This trial is ongoing. It must report results 3 weeks, 6 days from now.

Full data

Full entry on NCT04377659
Title A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date May 1, 2020
Completion date Oct. 28, 2022
Required reporting date Oct. 28, 2023, midnight
Actual reporting date None
Date last checked at April 10, 2023
Days late None